Talking Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Improving Outcomes of Frontline Treatment and Mitigating Relapse:
TKIs for Frontline Treatment
AMA Activity
Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.
This certified AMA activity will highlight the practice-changing updates in the frontline treatment of Ph+ ALL and provide guidance on effective implementation of new evidence through expert-guided discussions and interactive case scenarios.
FACULTY
Katarzyna Jamieson, MD
Associate Professor
University of North Carolina, Chapel Hill Department of Medicine
Farhad Ravandi, MD
Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Richard Stone, MD
Chief of Staff
Director of Translational Research
Adult Leukemia Program
Dana Farber Cancer Institute
Review each video at bit.ly/3CrQIa6 to claim AMA credit/contact hour(s) after completion of the brief Post-Test/Evaluations.
This activity is provided in collaboration with The University of Cincinnati and Practice Point Communications,
Supported by an independent educational grant from Amgen.